Article
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies
2024-12-20
Abstract excerpt
<h4>ABSTRACT</h4> Receptor tyrosine kinase ERBB4 (HER4) is frequently mutated in human cancer, and ERBB4 mutations have been identified in patients relapsing on targeted therapy. Here, we addressed the functional consequences of recurrent cancer-associated ERBB4 mutations that are located at regions important for dimer interactions and/or are paralogous to known oncogenic hotspot mutations in other ERBB genes....
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f7fcfa9d-11ac-55ac-95eb-07123a6d9257
- DOI
- 10.1101/2024.12.19.626686
